HTL Biotechnology at IMCAS 2026: advancing the future of regenerative medicine

A strong presence at the heart of IMCAS 2026

Throughout the congress, HTL Biotechnology’s projects and expertise were showcased through several key moments, including the Biopolymers Portfolio Symposium, the HA Roundtable hosted by La Tribune, the Innovation Tank, and numerous interactions at the HTL booth.

These highlights reflected the richness, diversity, and scientific excellence of HTL’s biopolymer portfolio, as well as the company’s ability to support its partners with innovative and reliable solutions.

Building the future of regenerative medicine

IMCAS 2026 once again confirmed the central role of collaboration between industry experts, physicians, and partners in shaping the future of regenerative medicine.

HTL Biotechnology is proud of its teams, grateful for the trust of its clients and partners, and fully committed to pursuing its mission: to push the boundaries of science and contribute to the development of next-generation regenerative solutions.